Replies to post #1414 on Antares Pharma, Inc. (ATRS)

[Bsav88atty]

I'm not sure I heard that, but I will defer to others here.

By the way, Bio, thanks for the private message. I share your concerns, though I will reiterate that Otrexup is much more user-friendly than the current sq products in the EU. That said, I'm unsure at which point the cost difference for that benefit will have a significant impact on market share penetration. I guess we'll have to see. The good news is, the U.S. market is wide open.